“…Locoregional disease control rates of approximately 40-70% [2,3,6,11,15,17,18,20,21,24,26,27,30] or even less [4,9,13] are reported for hypopharyngeal cancer (HC) patients receiving three-dimensional conventional radiation therapy (3DCRT) ± chemotherapy, while late-term dysphagia rates range between 40% and 75% in the majority of published articles [1,6,19,20,28]. The main challenge in conventional irradiation of HC is an appropriate dose coverage mainly to the dorsal aspect of the tumor and the boost planning target volume (PTV1), respectively, which is often close to or overlaps the spinal cord in the lateral-beam projection used for 3DCRT.…”